Trial Profile
A study evaluating relationship between behavioral and neuropsychiatric symptoms and tau deposition using 18F-THK5351 in patients with Alzheimer's disease and mild cognitive impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Fluorine 18 THK 5351 (Primary) ; Flutemetamol-F-18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- 24 Aug 2017 New trial record
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017